Alvotech Warrant (NASDAQ:ALVOW)
| Market Cap | 3.44B-66.0% |
| Revenue (ttm) | 491.95M-12.2% |
| Net Income | -179.59M-383.5% |
| EPS | -0.63-435.1% |
| Shares Out | 312.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,455 |
| Open | 1.52 |
| Previous Close | 0.31 |
| Day's Range | 0.36 - 1.52 |
| 52-Week Range | 0.36 - 1.52 |
| Beta | 0.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 11, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About ALVOW
Alvotech Holdings SA is an Icelandic enterprise that, operating via its subsidiary companies, undertakes the development and fabrication of biosimilar pharmaceuticals destined for international consumption.
$ALVOW stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ALVOW holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ALVOW's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ALVOW Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ALVOW Revenue by Segment or Geography
Source: SEC EDGAR (10-Q/10-K)
U.S. Patents
New ALVOW patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ALVOW from public contracts
Source: USAspending.gov
ALVOW Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ALVOW’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.